Arkady V. Nekrasov

Founder of NPO Petrovax Pharm, Professor, Doctor of Chemistry, Winner of Russian State Award

  • Foundation of Petrovax Pharm.
  • Marketing authorization of Polyoxidonium® and Grippol®.
  • Prof. Arkady V. Nekrasov and his development team are awarded the State Prize of the Russian Federation for Polyoxidonium® and Grippol® creation and implementation in the public healthcare practice.
  • Launch of the production facility to manufacture APIs, semi-solid and solid dosage forms (tablets), and injectables.
  • The start of partnership with Solvay Pharma (currently, Abbott).
  • Approval of Azoximer bromide as the INN for Polyoxidonium® by the World Health Organization (WHO).
Полиоксидоний - таблетки 12 мг - Вправо.jpgIn 2002, the development team led by prof. Arkady V. Nekrasov was awarded the State Prize of the Russian Federation for Polyoxidonium® and Grippol® creation and implementation in the public healthcare practice.
  • Launch of Longidaza®.
  • Opening of a state-of-the-art manufacturing and warehouse complex complying with GMP standards in Pokrov Village (Podolsk District, Moscow Region).
  • Launch of a unique prefilled syringe filling line.
  • Launch of Grippol® Plusa preservative-free innovative influenza vaccine.
  • Development and production of A/H1N1 pandemic influenza vaccines: MonoGrippol Neo, MonoGrippol Plus, and MonoGrippol.
  • Production of Grippol® Plus vaccine for the National Immunization Schedule.
  • Launch of the project on the manufacturing localization of a 13-valent pneumococcal conjugate vaccine (in partnership with Pfizer). The project wins a Russian Platinum Ounce award.
  • Successful completions of the EU GMP audit.
  • EU GMP audit successful completion.
  • Acquisition of NPO Petrovax Pharm controlling interest by Interros Group owner and founder Vladimir Potanin’s company.
  • Signing of agreements on the localization of Grippol Plus influenza vaccine in the Republic of Belarus and Iran.
  • Launch of Imoferaza®, an innovative special care cosmetic cream for post-trauma, post-surgical, and post-acne scars.
  • Approval of the bovhyaluronidase azoximer as the INN for azoximer as the INN for Longidaza® by the World Health Organization.
  • A license of the Russian Ministry of Health to manufacture Grippol® Plus, a Russian influenza vaccine, using flu antigens produced by St. Petersburg Research Institute for Vaccines and Sera of Russia’s Federal Medical and Biological Agency.
  • The start of partnership with Boehringer Ingelheim to localize full-cycle manufacturing of advanced cardiovascular pharmaceutical products. The launch of the first commercial batches of Metalyse®.
  • Extension of the Polyoxidonium®tablets label to include pediatric patients aged 3 years and over. Successful completion of a Post-Authorization Safety Study (PASS) for Polyoxidonium® tablets label is extended to include children aged 3+ years. A Post-Authorization Safety Study (PASS) for Polyoxidonium® in Europe (Slovakia).
  • Recognition of NPO Petrovax Pharm as the winner of the All-Russia Contest “Russian Business Leaders: Performance and Commitment 2017” in the category “For the Dynamic Development of Business.”
  • Completion of the clinical trials of Grippol® Quadrivalent, the first Russian 4-valent inactivated influenza vaccine. The registration dossier is submitted.

Grippol Welson

  • Launch of Grippol® Quadrivalent, the first Russian 4-valent influenza vaccine. Expansion of Petrovax’s product portfolio due to Velson® (INN: melatonin) that promotes falling asleep faster and improves sleep quality.
  • Celebration of the 10th anniversary of NPO Petrovax Pharm manufacturing complex; presentation of a new (3rd) manufacturing line for APIs, tablets, and suppositories. The new manufacturing line is licensed and awarded with the Russian GMP certificate. The compliance of the manufacturing processes and the Quality Management System (QMS) with the applicable EU GMP regulations (Slovakia) is confirmed. The first batches of Polyoxidonium® labeled in accordance with the mandatory EU requirements are supplied to Slovakia.
  • Petrovax Pharm’s products wins the 7th Russian Pharma Awards contest: Polyoxidonium® in the category The Drug of Choice for ARVI and Influenza Prevention in Children; Longidaza® in the category The Drug of Choice for Pathogenetic Therapy of Chronic Prostatitis and Relapse Prevention.
  • Rebranding. The new corporate style reflects the new corporate strategy aimed at expanding the product portfolio and intensive international integration achievement. The brand preserves its consistency and unique identity, however, becoming more concise and up-to-date.
1.png Petrovax

  • Large-scale clinical trials of originator drugs Polyoxidonium® and Longidaza® in the prevention and treatment of COVID-19.
  • Commissioning the second manufacturing facility for manufacturing of APIs, soft and solid dosage forms. The line allowed for an increase in the manufacturing of APIs by 2.5 times, suppositories by 4 times and tablets by 7 times.
  • Implementation of the Russian-Chinese project on the development and subsequent manufacturing of Convidicea, a recombinant adenovirus-based viral vector vaccine for the prevention of COVID-19 in cooperation with CanSino Biologics Inc. (China).
  • Launch of new products:
  • Uronext®, a complex remedy for urinary tract infections.
  • VitaFerr®, a combination product for iron deficiency prevention in women.
  • Polyoxidonium® solution, a new dosage form.
  • Charity support of the Podolsk City Hospital in equipping a specialized COVID-19 hospital. More than 20,000 packages of Polyoxidonium® are supplied to healthcare professionals working in “red zones” for COVID-19 prevention.

© Petrovax
The materials posted on the site are for informational purposes only and are not intended to advertise or promote the manufacturer or medications produced.